Islet Management engages OraSure on board changes for OraSure Technologies stock
Islet Management has engaged OraSure Technologies' board and management regarding stockholder value and potential board changes. This engagement follows a significantly improved second quarter for OraSure, which saw a return to GAAP profitability with $6.20 million in net income, despite a slight year-over-year revenue decrease. OraSure's stock price saw a modest increase on October 2, 2026, as investors weigh the company's improved margins and activist pressure.
A 4,797-share grant replaces cash fees for OraSure (OSUR) director Steven Kyle Boyd.
OraSure Technologies director Steven Kyle Boyd acquired 4,797 common shares on September 29, 2026, at $3.88 per share. These restricted shares, which vested immediately, were issued in place of cash director fees as per Boyd's election under the company's Director Compensation Policy. Following this grant, Boyd's direct holdings in OraSure Technologies increased to 168,031 shares.
Investor group reports 6.40 percent stake in OraSure Technologies stock
An investor group, including Islet Management and Yorkville-affiliated funds, has acquired a 6.40% stake in OraSure Technologies, prompting discussions about potential board changes and capital allocation. This comes as OraSure reported a GAAP net income in Q2 2026, though operating losses persisted and revenue growth was mixed. The disclosed stake introduces governance pressure as investors evaluate the company's financial performance.
OraSure Technologies stock falls 1.5 percent as stake emerges
OraSure Technologies (OSUR) stock fell 1.5% to USD 3.93 on September 24, 2026, after a new investor group, including Islet Management and Yorkville affiliated funds, disclosed a 6.4% stake and indicated potential strategic engagement. This comes as the company reported improved Q2 2026 GAAP profit of USD 6.2 million, despite a 2% year-over-year revenue decline and a decrease in cash reserves. The activist stake and recent profit turnaround are key factors for the stock, which remains below its yearly high.
OraSure Technologies stock gains 8.13 percent on September 23
OraSure Technologies (OSUR) stock saw an 8.13 percent increase on September 23, 2026, closing at USD 3.99. This places the stock 31.2 percent below its 52-week high of USD 5.80 and 45.6 percent above its 52-week low of USD 2.74. With a market capitalization of USD 6.017 million and low trading volume, the company remains a small-cap stock.
Perspective: First-Void Urine - A New Era in Accessible STI Testing
This article, titled "Perspective: First-Void Urine - A New Era in Accessible STI Testing," highlights the potential of first-void urine as a more accessible and convenient method for STI testing. It suggests that this approach could usher in a new era for improving public health by making testing easier for individuals.
Investor group at OraSure Technologies (OSUR) may seek board seats and a possible sale
A new investor group, comprising Islet Management and Yorkville-affiliated funds, has acquired a 6.4% stake in OraSure Technologies (OSUR), believing the shares are undervalued. The group, formed on September 11, 2026, aims to enhance stockholder value, potentially by nominating directors for the 2027 annual meeting and discussing changes to capital allocation, ownership structure, or even a company sale. Islet Management also holds economic exposure to an additional 0.7% of shares through cash-settled total return swaps.
Yorkville Advisors Pushes for Changes at OraSure Technologies with 6.4% Stake
Yorkville Advisors and Islet Management have collectively acquired a 6.4% stake in OraSure Technologies, Inc., leading to the filing of a Schedule 13D. The group intends to engage with OraSure's board and management to enhance stockholder value, including potential director nominations at the 2027 annual meeting. Their strategy focuses on influencing strategy, capital allocation, and exploring options to boost company performance.
OraSure Technologies (OSUR) director reports tax withholding on vested shares
OraSure Technologies director John P. Kenny reported a transaction where 5,116 shares of common stock were withheld to cover tax liabilities associated with the vesting of restricted shares. The shares were withheld at a price of $3.4275 per share on September 6, 2026. Following this transaction, Kenny directly holds 204,598 shares of OraSure Technologies.
Orasure Technologies Stock Price Forecast. Should You Buy OSUR?
StockInvest.us rates OraSure Technologies (OSUR) as a Strong Sell Candidate with a technical score of -5.19. The stock price fell by -0.88% on September 9, 2026, and has been in a falling trend, with a forecasted 17.99% fall over the next three months. The analysis indicates several negative technical signals and recommends a negative evaluation due to the weak short-term performance and lack of support.
BlackRock Inc. Takes $27.91 Million Position in OraSure Technologies, Inc. $OSUR
BlackRock Inc. has acquired a new stake of 6.26 million shares in OraSure Technologies, Inc., valued at approximately $27.91 million, making them a significant shareholder with 9.09% ownership. Despite this substantial investment, analyst sentiment remains cautious with a "Reduce" consensus rating and a target price of $3.00, which is below the recent trading price of $3.61. Other institutional investors have also adjusted their positions in the medical instruments supplier, which has a market capitalization of $248.98 million and a P/E ratio of -5.23.
Private Management Group Inc. Cuts Stake in OraSure Technologies, Inc. $OSUR
Private Management Group Inc. reduced its stake in OraSure Technologies (NASDAQ:OSUR) by 30% in the second quarter, selling 1.62 million shares and retaining 3.80 million shares valued at approximately $16.9 million. Despite this, institutional investors collectively own 93.5% of OSUR's shares, with several other firms establishing new positions. OraSure Technologies, a diagnostic and medical device company, opened at $3.60, below the consensus price target of $3.00, and has a "Reduce" rating from analysts.
Cannell Capital LLC Purchases New Holdings in OraSure Technologies, Inc. $OSUR
Cannell Capital LLC has acquired a new position in OraSure Technologies, Inc. (NASDAQ:OSUR), purchasing over 1.4 million shares valued at approximately $6.37 million during the second quarter of 2026. This move makes OraSure Technologies the 9th largest holding for Cannell Capital, representing about 2.07% of the company. Despite significant institutional ownership (93.5%), analyst sentiment remains cautious with a "Reduce" rating and a target price of $3.00, while the stock recently traded down 2.4% at $3.60.
3,613,836 Shares in OraSure Technologies, Inc. $OSUR Acquired by Altai Capital Management L.P.
Altai Capital Management L.P. has acquired 3,613,836 shares of OraSure Technologies, Inc. ($OSUR), valued at approximately $16.1 million, making it their second-largest holding and representing 5.24% of the company. Institutional investors now own about 93.5% of OSUR, despite analysts maintaining a "Reduce" rating and a $3.00 price target for the stock. OraSure Technologies specializes in diagnostic and medical device products, including the OraQuick rapid HIV test.
Earnings Preview: OSUR to Report Financial Results Post-market on August 05
This article announces that OSUR is scheduled to report its financial results after the market closes on August 5th. It serves as an earnings preview, alerting investors and stakeholders to the upcoming release of the company's financial performance data.
OraSure Technologies (NASDAQ:OSUR) Gains FDA Nod for Rapid Antigen Test
OraSure Technologies (NASDAQ:OSUR) recently received FDA authorization for a rapid antigen test and a urine-collection sample kit, expanding its reach in at-home diagnostic testing. This development highlights the company's focus on non-invasive sampling and accessible diagnostics, positioning it well within the growing trend of decentralized healthcare. OraSure's debt-free status also provides financial resilience in a dynamic market environment.
OraSure Technologies, Inc.: Target Price Consensus and Analysts Recommendations | OSUR | US68554V1089
This article provides an overview of analyst recommendations and target price consensus for OraSure Technologies, Inc. (OSUR). It details recent changes in analyst ratings and price targets from various firms like JPMorgan, Citigroup, Evercore ISI, and Stephens, dating back to 2021. The consensus currently shows a "HOLD" rating with an average target price of $4.00, reflecting a slight upside from the last closing price.
OraSure Technologies(OSUR) Stock Options Chain | Quotes & News
This article provides access to the stock options chain, quotes, and news for OraSure Technologies (OSUR). It likely includes financial data and relevant information for investors interested in the company's stock and options.
OraSure (OSUR) Q2 2026 Earnings Call Transcript
OraSure Technologies (OSUR) reported Q2 2026 earnings, exceeding revenue guidance with $30.6 million and showing sequential growth in Diagnostics and Sample Management Solutions. The company highlighted FDA clearances for the Colli-Pee urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 test, underscoring its decentralized diagnostics strategy. While the FDA submission for the IntelliQ CT/NG test was withdrawn for resubmission, management reiterated its commitment to 2026 revenue growth and achieving operating cash flow breakeven by early 2027.
Kaltura, Inc. (OSUR): Neil Gagnon group reports 5.8% ownership stake
The Neil Gagnon group has reported a 5.8% beneficial ownership stake in Kaltura, Inc., totaling 8,869,949 shares of common stock. This ownership is distributed among Neil Gagnon personally, Gagnon Securities LLC, and Gagnon Advisors, LLC, with specified sole and shared voting and dispositive powers. The filing clarifies that the group disclaims beneficial ownership of shares held in client and fund accounts.
Enterprise value to EBIT forward of OraSure Technologies, Inc. – BX:EP3
This article provides financial information for OraSure Technologies, Inc. (BX:EP3), specifically focusing on its enterprise value to EBIT forward. The content is presented within the TradingView platform, offering an overview of the company's financial data.
Dimensional Fund Advisors LP Sells 437,763 Shares of OraSure Technologies, Inc. $OSUR
Dimensional Fund Advisors LP reduced its stake in OraSure Technologies by 13.4%, selling 437,763 shares but still holding 2.82 million shares valued at $8.46 million, representing 3.92% of the company. Despite institutional ownership at 93.5%, and a recent insider purchase, analysts maintain a "Reduce" rating with a $3.00 price target, while the stock opened at $4.05, near its 52-week high.
Wall Street Zen Upgrades OraSure Technologies (NASDAQ:OSUR) to Hold
Wall Street Zen has upgraded OraSure Technologies (NASDAQ:OSUR) from a "sell" to a "hold" rating, while Weiss Ratings also improved its rating from "sell (e+)" to "sell (d-)". Despite this, analysts collectively rate the stock as "Reduce" with an average price target of $3.00. The stock opened at $4.05, near its 52-week high, with significant institutional ownership and recent insider buying.
OraSure Technologies, Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
OraSure Technologies, Inc. reported a surprise profit in its latest quarterly results, leading analysts to significantly upgrade their earnings forecasts for the company. While revenue projections remain largely unchanged, the improved profit outlook suggests a positive shift in the company's financial performance according to the updated analyst models.
OraSure Technologies (OSUR) Stock Profit Return Faces Cash Flow Doubts
OraSure Technologies (OSUR) recently swung from a deep quarterly loss to a profit of US$0.09 EPS on US$30.6 million revenue, which was a positive development for the diagnostics and sample management specialist. Despite the improved gross margin and new product launches, the stock price reaction was muted, and skeptics point to declining trailing twelve-month revenue and negative operating cash flow as ongoing concerns. Management aims for operating cash flow breakeven by 2027, but the company faces challenges with lumpy funding and execution risks.
OraSure Technologies (OSUR) Stock Profit Return Faces Cash Flow Doubts
OraSure Technologies (OSUR) recently swung to a quarterly profit with a positive EPS of US$0.09 and increased revenue, driven by new product launches and manufacturing insourcing. Despite these positive indicators like improved GAAP gross margin and operating income, the share price reaction was modest, and skeptics point to a decline in trailing twelve-month revenue and negative operating cash flow as concerns about the repeatability and quality of the turnaround. Management is still targeting operating cash flow breakeven in 2027, but issues like a withdrawn product submission add to execution risks.
ORA SURE TECHNOLOGIES INC 2026: Revenue $30.64M, Net income $6.25M, EPS $0.09— 10-Q Summary
OraSure Technologies Inc. (OSUR) reported its financial results for the quarter ended 2026, showing revenue of $30.64M, net income of $6.25M, and diluted EPS of $0.09. This represents a significant improvement compared to the prior-year quarter, which saw a net loss of ($19.69M) and loss per share of ($0.26), despite a slight decrease in revenue. The company highlighted improved gross margin, strategic product shifts, and key regulatory milestones such as FDA clearance for Colli-Pee® Dx and EUA for OraQuick™ Ebola 2.0.
ORA SURE TECHNOLOGIES INC 2026: Revenue $30.64M, Net income $6.25M, EPS $0.09— 10-Q Summary
OraSure Technologies Inc. (OSUR) reported its quarterly results for 2026, showing revenue of $30.64M, net income of $6.25M, and diluted EPS of $0.09. This represents a significant improvement compared to the prior year, which saw a net loss of ($19.69M) and an EPS of ($0.26), despite a slight revenue decline. The company highlighted operational efficiencies, regulatory clearances for new products, and a strategic focus on R&D for CT/NG and Colli-Pee® trials.
OraSure Technologies Q2 Earnings Call Highlights
OraSure Technologies reported Q2 revenue of $30.6 million, surpassing guidance, driven by strong public-health diagnostics and sample-management product growth. The company achieved sequential gross-margin improvement and significant regulatory milestones, including FDA clearance for its Colli-Pee Dx urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 Rapid Antigen Test. Despite withdrawing its IntelliQuick CT/NG test submission for resubmission, OraSure remains confident in its cash position, expects to reach break-even cash flow from operations by early 2027, and projects Q3 revenue between $29.5 million and $32.5 million.
OraSure Technologies Inc (OSUR) (Q2 2026) Earnings Call Highlights: Revenue Surges 9. ...
OraSure Technologies (OSUR) reported strong Q2 2026 results, with total revenue exceeding guidance at $30.6 million, a 9.7% sequential increase, driven by diagnostic and sample management product growth. The company achieved regulatory milestones, including FDA clearance for Colli-Pee Dx and EUA for OraQuick Ebola 2.0, and maintains a solid financial position with $161 million in cash. However, OSUR withdrew its FDA submission for the InteliQuick CT/NG test, delaying its launch, and reported a non-GAAP operating loss of $14.7 million for the quarter.
OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies, Inc. (OSUR) reported its financial results for the second quarter of 2026. The company announced its performance during this period, which is a key indicator of its operational health and market standing. This update provides investors and stakeholders with crucial insights into OraSure's recent financial activities and future prospects.
OraSure Technologies, Inc. Q2 2026 Earnings Call Summary
OraSure Technologies, Inc. characterizes 2026 as a transition year, focusing on executing a focused growth strategy after restructuring. The company reported sequential revenue growth and gross margin expansion, driven by public health demand and operational efficiencies, despite withdrawing an FDA submission for a molecular test to incorporate feedback. Management remains committed to achieving operating cash flow breakeven by 2027 and is prioritizing balance sheet flexibility for future investments.
OraSure Technologies Q2 Earnings Call Highlights
OraSure Technologies (NASDAQ: OSUR) reported strong Q2 results, exceeding revenue guidance with $30.6 million, driven by increased public-health demand and growth in diagnostic and sample-management products. The company achieved key regulatory milestones, including FDA clearance for its Colli-Pee Dx urine collection kit and Emergency Use Authorization for the OraQuick Ebola 2.0 test, despite delaying the U.S. launch of its IntelliQuick CT/NG test. OraSure improved its gross margin to 43.5%, ended the quarter debt-free with $161 million in cash, and expects Q3 revenue between $29.5 million and $32.5 million, targeting operating cash-flow break-even by early 2027.
Earnings call transcript: OraSure tops Q2 2026 revenue forecast, shares jump
OraSure Technologies exceeded its Q2 2026 revenue forecast, reporting $30.6 million against an expected $28.83 million, leading to a 6.92% jump in after-hours trading. The company highlighted improving gross margins, new product clearances like Colli-Pee Dx and OraQuick Ebola 2.0, and a strong balance sheet with $161 million in cash and no debt. Despite a delay in the IntelliQuick CT/NG test's FDA clearance, management remains confident in its 2026 revenue growth outlook and target of operating cash flow break-even by early 2027.
OraSure Q2 2026 Earnings: A $22.6 Million Remeasurement Drove GAAP Profit
OraSure Technologies reported Q2 2026 net revenue of $30.6 million, a 2% decrease year-over-year, but achieved GAAP profitability with diluted EPS of $0.09, up from a loss of $0.26. This GAAP profit was primarily due to a $22.6 million reduction in acquisition-related contingent consideration, rather than operational improvements, as non-GAAP operating loss widened to $14.7 million. The company faces ongoing challenges including substantial underlying operating losses, regulatory risks for its CT/NG program, flat core revenue growth, and declining cash reserves.
Press Release: OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies has announced its financial results for the second quarter of 2026. The company reported its performance, providing key figures and insights into its operations during this period. Further details on revenue, expenses, and profitability are expected to be included in the full financial statement.
OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies, Inc. announced its financial results for the second quarter of 2026, reporting total revenue of $30.6 million, a 9.7% sequential increase and above guidance, with improved gross margin. The company also highlighted recent FDA clearances for its Colli-Pee™•Dx at-home urine collection device and Emergency Use Authorization for its OraQuick™ Ebola 2.0 Rapid Antigen Test. OraSure provided Q3 2026 revenue guidance of $29.5 million to $32.5 million and discussed its strategic focus on decentralizing diagnostics and targeted growth initiatives.
OraSure Announces Second Quarter 2026 Financial Results
OraSure Technologies, Inc. announced its Q2 2026 financial results, reporting $30.6 million in revenue, a 9.7% sequential increase, and improved gross margin. The company also highlighted key achievements, including FDA clearance for its Colli-Pee™•Dx at-home urine collection device and Emergency Use Authorization for its OraQuick™ Ebola 2.0 Rapid Antigen Test. Despite a year-over-year revenue decrease of 2%, OraSure is pursuing growth initiatives through innovation and strategic collaborations, with Q3 2026 revenue guidance set between $29.5 million and $32.5 million.
OraSure Technologies, Inc. Revenue Breakdown – NASDAQ:OSUR
OraSure Technologies, Inc. (NASDAQ: OSUR) reported total revenue of $115.02 million USD last year. The Human Immunodeficiency Virus segment was its top performer, generating $49.80 million USD, though this was a decrease from $60.80 million USD in the prior year. The United States was the primary revenue contributor, accounting for $78.25 million USD.
OraSure Technologies (OSUR) investor discloses 5.5% stake in common stock
Private Management Group, Inc., an investment adviser, has disclosed a 5.5% beneficial ownership stake in OraSure Technologies Inc. (OSUR) common stock, totaling 3,797,682 shares as of June 30, 2026. The firm holds sole voting and dispositive power over these shares, which are managed across various separately managed accounts. The account holders are entitled to receive dividends and sale proceeds from these shares.
OraSure Technologies Inc (OSUR) Financial Health: Profitability & Balance Sheet Analysis
OraSure Technologies Inc (OSUR) currently holds a financial score of 6.97, placing it 116th out of 199 companies in the Healthcare Equipment & Supplies industry. While its financial status is deemed robust, its operational efficiency is low. The company recently reported a quarterly revenue of $27.93 million, marking a 6.70% year-over-year decrease, with net profit declining by 39.51% over the same period.
OraSure Technologies Inc (OSUR) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for OraSure Technologies Inc (OSUR), detailing its current risk score, industry ranking, and beta value. It includes various financial metrics such as volatility, maximum drawdown, Sharpe Ratio, and liquidity indicators. The report also notes the neutral impact of the U.S. Dollar Index on the Healthcare Equipment & Supplies industry.
OraSure Technologies (OSUR) Expected to Post Earnings on Wednesday
OraSure Technologies (NASDAQ:OSUR) is scheduled to release its Q2 2026 earnings after market close on Wednesday, August 5th. Analysts anticipate a loss of $0.27 per share on revenue of $28.85 million. Despite a consensus "Reduce" rating and an average price target of $3.00, the stock has seen recent insider buying and increased institutional holdings.
OraSure Technologies Inc (OSUR) Income Statement
This article provides a detailed income statement for OraSure Technologies Inc (OSUR), offering quarterly and annual financial performance data. It includes key metrics such as total revenue, cost of revenue, operating expenses, and net income, allowing users to analyze the company's operational efficiency and profitability over several fiscal periods. The article also provides a FAQ section to help users understand how to interpret the income statement and identifies essential metrics for stock analysis.
OraSure Technologies Inc (OSUR) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the major shareholders and institutional holdings of OraSure Technologies Inc (OSUR), including top individual institutional investors and types of shareholder entities. It provides a breakdown of institutional shareholding over recent quarters, displaying the number of institutions, shares held, proportion, and changes. The report also lists ETFs that hold OSUR stock and their respective proportions.
OSUR|OraSure Technologies Inc|Price:3.800|
This article provides a detailed company profile of OraSure Technologies Inc (OSUR), including its background, business scope, and financial data. It highlights the company's focus on decentralizing diagnostics with rapid diagnostic tests and sample collection devices, and lists key executives, institutional shareholdings, and top revenue generators.
OSUR|OraSure Technologies Inc|Price:3.970|Chg%:-0.060
This article provides a detailed financial overview of OraSure Technologies Inc (OSUR), including its income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS, revenue, net profit, and margins across various quarters and fiscal years. The report indicates OraSure Technologies Inc's latest earnings date as August 5, 2026, with an analyst rating of "BUY".
OraSure Technologies Inc (OSUR) Cash Flow
This article provides a detailed quarterly and annual cash flow statement for OraSure Technologies Inc (OSUR), covering operating, investing, and financing activities. It presents extensive financial data including net income, capital expenditures, and free cash flow, alongside explanations of what each cash flow type signifies. The report also addresses frequently asked questions regarding OSUR's cash flow performance and definitions of cash flow metrics.
OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for OraSure Technologies Inc (OSUR), categorizing its income by business segments and geographical regions. It highlights that HIV products account for the largest proportion of net product and services revenues, and the United States is the primary regional revenue contributor. The data is presented with proportions for each category, offering insights into the company's financial structure.
OSUR|OraSure Technologies Inc|Price:3.975|Chg%:+0.005
OraSure Technologies Inc (OSUR) shows healthy fundamentals and significant growth potential, despite recent weak stock market performance. The stock is considered fairly valued within the Healthcare Equipment & Supplies industry, with a high institutional ownership. Analysts have rated it as a Buy, with a target price of $5.00, suggesting an upward trend in the medium term.
